NCT06005974View on ClinicalTrials.gov

A Study of REC-4881 in Participants with Cancers Which Have an AXIN1 or APC Mutation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
AXIN1 Gene MutationAPC Gene MutationSolid Tumor
Interventions
DRUG

REC-4881

REC-4881 4mg capsules

Trial Locations (13)

19713

Medical Oncology Hematology Consultants, Newark

20817

American Oncology Partners of Maryland, PA, Bethesda

22031

Virginia Cancer Specialists, Fairfax

32003

Cancer Specialists of North Florida, Fleming Island

50314

Mission Cancer And Blood, Des Moines

57105

Avera Cancer Institute, Sioux Falls

64111

Saint Luke's Hospital, Kansas City

75231

Mary Crowley Cancer Research Centers, Dallas

80218

Rocky Mountain Cancer Centers, Denver

92123

Sharp Memorial Hospital, San Diego

93105

Sansum Clinic, Santa Barbara

06360

Eastern Connecticut Hematology & Oncology Associates, Norwich

08844

Hunterdon Hematology Oncology, Hillsborough

All Listed Sponsors
lead

Recursion Pharmaceuticals Inc.

INDUSTRY

NCT06005974 - A Study of REC-4881 in Participants with Cancers Which Have an AXIN1 or APC Mutation | Biotech Hunter | Biotech Hunter